Last €7.54 EUR
Change Today -0.035 / -0.46%
Volume 0.0
EVTA On Other Exchanges
As of 11:14 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

evotec ag - spon adr (EVTA) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/28/14 - €8.59
52 Week Low
10/16/14 - €4.87
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EVOTEC AG - SPON ADR (EVTA)

Related News

No related news articles were found.

evotec ag - spon adr (EVTA) Related Businessweek News

No Related Businessweek News Found

evotec ag - spon adr (EVTA) Details

Evotec AG, together with its subsidiaries, provides drug discovery solutions for pharmaceutical and biotechnology companies, and academic institutions worldwide. Its services comprise target ID and validation, hit identification, compound management, chemistry, ADME (absorption, distribution, metabolism and excretion) profiling, proteomics, reagent production, in vitro pharmacology, in vivo pharmacology, and integrated services. The company has various products under clinical stage comprising DiaPep277 for diabetes type 1; EVT3021 for Alzheimer's disease; EVT201 for insomnia; Somatoprim for Acromegaly; EVT1032 for TRD; EVT401 inflammation; and ND³ for oncology. It also has various pre-clinical stage products, including ND³ for pain and oncology; endometriosis products; and EVT770 for diabetes type 2/1, as well as discovery stage products comprising EVT070 for diabetes type 2; and various products for inflammation, diabetes type 2, diabetes type 2/1, kidney disease, and Alzheimer’s disease. The company has alliances and partnerships with various companies comprising AstraZeneca AB, Bayer Pharma AG, Boehringer Ingelheim Pharma GmbH & Co. KG, CHDI Foundation, Inc., MedImmune, LLC/AstraZeneca PLC, Genentech, Inc., the Jain Foundation, Janssen Pharmaceuticals, Inc., Johnson & Johnson Innovation, Ono Pharmaceutical Co., Ltd., UCB Pharma, and Fraunhofer Institute for Molecular Biology and Applied Ecology; and collaboration with Eternygen GmbH and C4X Discovery Holdings plc. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.

718 Employees
Last Reported Date: 11/12/14
Founded in 1993

evotec ag - spon adr (EVTA) Top Compensated Officers

Chief Executive Officer and Member of Managem...
Total Annual Compensation: €601.0K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €360.0K
Chief Operating Officer and Member of Managem...
Total Annual Compensation: €409.0K
Chief Scientific Officer and Member of Manage...
Total Annual Compensation: €372.0K
Compensation as of Fiscal Year 2013.

evotec ag - spon adr (EVTA) Key Developments

Evotec Ag and C4X Discovery Holdings plc Enters Research Collaboration to Identify Pre-Clinical Development Candidates for Stress-Related Addictive Disorder Programme

Evotec AG announced a research collaboration with C4X Discovery Holdings plc to optimise Orexin-1 selective inhibitors discovered through C4XD's unique NMR technology. Evotec will apply its drug discovery platform with C4XD to further develop several series of Orexin-1 selective inhibitors. Activation of the orexin-1 receptor in the brain is associated with stress-related addictive disorders (e.g. for alcohol, nicotine, cocaine and opiates), while the activation of the orexin-2 receptor is associated with biorhythms and wakefulness. Identification and development of selective compounds that inhibit the orexin-1 pathway thus should provide treatments for addiction avoiding the sedative effects associated with inhibition of orexin-2.

Evotec AG Extends Collaboration Agreement with Padlock Therapeutics, Inc

Evotec AG has extended its collaboration agreement with Padlock Therapeutics Inc. for developing inhibitors of protein-arginine deiminases, or PADs. The collaboration initially began in January 2014 and now extends through March 2017. As part of the collaboration, Evotec provides a full range of research activities and expertise to Padlock including in vitro biology, high-throughput screening, structural biology, medicinal and computational chemistry and DMPK. Over the next period, Evotec and Padlock will progress multiple programmes through hit-to-lead and lead optimisation with the goal of delivering multiple development candidates. Under the terms of the initial agreement, Evotec was awarded a success payment and equity grant in addition to research payments. In the next phase of this agreement, Evotec is eligible for over $13 million in research payments and milestones.

Evotec Announces Research Collaboration with OSUCCC for Cancer Therapy

Evotec AG has announced a research collaboration with the laboratories of Roger Briesewitz at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, or OSUCCC - James. The objective of the collaboration is to progress a novel mechanism for engaging the KRas target discovered at The Ohio State University using Evotec's technology platform and broad expertise in drug discovery and preclinical development, thereby validating and progressing novel leads into pharmaceutically developable candidates. KRas is a small GTPase regulating the RAS/MAPK signalling cascade that governs cell division. Mutations in KRas are early transforming events in tumourigenesis and are highly prevalent in lethal cancers such as lung, colon and pancreatic cancer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EVTA:GR €7.54 EUR -0.035

EVTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $2.34 USD -0.04
Cytokinetics Inc $7.71 USD -0.25
Exelixis Inc $2.93 USD 0.00
GlaxoSmithKline SAE £11.70 EGP 0.00
Infinity Pharmaceuticals Inc $15.20 USD -0.84
View Industry Companies

Industry Analysis


Industry Average

Valuation EVTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.3x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EVOTEC AG - SPON ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at